Clinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC

Simple item page
dc.contributor.authorKilickap, S.
dc.contributor.authorSezer, A.
dc.contributor.authorGumus, M.
dc.contributor.authorBondarenko, I.
dc.contributor.authorOzguroglu, M.
dc.contributor.authorGogishvili, M.
dc.contributor.authorTurk, H. M.
dc.contributor.authorCicin, I.
dc.contributor.authorBentsion, D.
dc.contributor.authorGladkov, O.
dc.contributor.authorClingan, P.
dc.contributor.authorSriuranpong, V.
dc.contributor.authorRizvi, N.
dc.contributor.authorLi, S.
dc.contributor.authorLee, S.
dc.contributor.authorMakharadze, T.
dc.contributor.authorPaydas, S.
dc.contributor.authorNechaeva, M.
dc.contributor.authorSeebach, F.
dc.contributor.authorWeinreich, D.M.
dc.contributor.authorYancopoulos, G.D.
dc.contributor.authorGullo, G.
dc.contributor.authorLowy, I.
dc.contributor.authorRietschel, P.
dc.date.accessioned2022-09-13T10:37:47Z
dc.date.available2022-09-13T10:37:47Z
dc.date.issued2021
dc.identifier.endpageS101en_US
dc.identifier.issn1556-0864en_US
dc.identifier.issue3en_US
dc.identifier.startpageS101en_US
dc.identifier.urihttp://hdl.handle.net/11727/7719
dc.identifier.volume16en_US
dc.identifier.wos000631349600072en_US
dc.language.isoengen_US
dc.relation.journalJOURNAL OF THORACIC ONCOLOGYen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectnon-small cell lung canceren_US
dc.subjectanti-PD-1en_US
dc.subjectcemiplimaben_US
dc.titleClinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLCen_US
dc.typeconferenceObjecten_US

Files

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Tıp Fakültesi / Faculty of Medicine
Wos İndeksli Yayınlar Koleksiyonu
Wos Kapalı Erişimli Yayınlar